Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 13, 2007. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary Shares by six individuals through the Company's ShareReward Plan on July 12, 2007. The shares were purchased at a price of GBP 12.69 per Ordinary Share under the Dividend Reinvestment element of the Plan. The specific acquisitions were:
- Mr J S Heslop: 13 Ordinary Shares
- Mr R Bondy: 13 Ordinary Shares
- Mr D Learmouth: 13 Ordinary Shares
- Dr D Pulman: 7 Ordinary Shares
- Mr C Viehbacher: 2 Ordinary Shares
- Mr A P Witty: 13 Ordinary Shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the aforementioned share transactions in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Investor Verification Points
- Verify the share price of GBP 12.69 per Ordinary Share on July 12, 2007.
- Confirm the total number of shares acquired by the listed directors and managers (58 shares total).
- Review the terms of the ShareReward Plan entered into on October 5, 2001, to understand the Dividend Reinvestment element.